Cell Genesys Set To License Phase III Cancer Immunotherapeutic; Final Data Likely In 2009
Interim data monitoring committee analysis raised no flags on the first of two trials of GVAX therapy in prostate cancer, CEO Sherwin reports.
Interim data monitoring committee analysis raised no flags on the first of two trials of GVAX therapy in prostate cancer, CEO Sherwin reports.